arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Biomea Fusion, Inc.

BMEA
$1.44 ▼ -0.26 (-15.04%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
8 Visible periods
18 Metrics
Peer-ranked Benchmarks
Price Chart
22
Health
Poor
Bearish
auto_awesome

Analytical Summary

Biomea Fusion, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $75.2M
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC -223.2% →
FCF / Share $-1.35 ↗
Trailing P/E —
Price / Book 3.5x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

8-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-61.80M
↑ +55.4% —
FCF / Share Free cash flow per share
$-1.35
↑ +59.5% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
2
Cash Quality ↑
71

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 8 years · 28 quarters